Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.

10/02/2026, 12:15 PM • The Motley Fool

Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.

Pfizer's stock has declined 34% over five years due to falling coronavirus product demand and patent expirations on key drugs. However, the company's recent strategic acquisitions (Seagen, Metsera, Biohaven), regulatory approvals, and cost restructuring efforts are showing positive results. With management confident in maintaining its 6% dividend yield and the stock trading at a reasonable 9.6x forward earnings, the pharmaceutical giant may now present a compelling opportunity for dividend investors.

10/02/2026, 4:03 AM • The Motley Fool

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

Artificial Intelligence (AI) in Life Sciences Market: Trends and Forecast to 2040 | Market to Reach USD 73.05 Billion at 20% CAGR as Drug Discovery and Precision Medicine Scale

The global AI in life sciences market is projected to expand from USD 5.69 billion in 2026 to USD 73.05 billion by 2040, driven by accelerating drug discovery, precision medicine adoption, and clinical trial optimization. AI technologies including machine learning, computer vision, and natural language processing are enabling faster R&D, reduced costs, and improved diagnostic accuracy. However, challenges include high development costs, data privacy concerns, AI bias, and regulatory validation requirements.

09/30/2026, 4:53 AM • GlobeNewswire

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two pharmaceutical giants with divergent strategies: Bristol Myers Squibb, a deep-value dividend payer trading at cheap multiples (P/E 14.07) with flat revenue but stabilizing earnings, versus Eli Lilly, a high-growth juggernaut riding explosive success in GLP-1 metabolic drugs with 45% revenue growth and a P/E of 40.26. Despite BMY's attractive valuation, the author recommends LLY for 2026 due to its strong growth trajectory, successful drug pipeline including Retatrutide and lipoprotein(a) therapeutics, and forecast for 30% revenue growth.

09/29/2026, 6:22 PM • The Motley Fool

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.

09/28/2026, 7:00 AM • GlobeNewswire

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

Despite being down 35% year-to-date, Alnylam Pharmaceuticals has rebounded 25% since late July and maintains strong analyst support with 18 of 21 analysts rating it as a buy or strong buy. The stock's attractive valuation (19.7x forward earnings, 0.32 PEG ratio) and favorable market dynamics—including reduced competition from a failed rival drug and extended patent protection for Pfizer's competing therapy—support the bullish outlook. However, investors should monitor demand normalization for Amvuttra and potential developments from the failed Wainua trial.

09/28/2026, 5:23 AM • The Motley Fool

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.

Federal Reserve Chair Kevin Warsh's hawkish stance signals sustained higher interest rates to combat inflation. While this increases competition for dividend stocks from Treasury bonds, big pharma dividend stocks like Pfizer, AbbVie, and Bristol Myers Squibb should remain resilient due to strong fundamentals and manageable debt service costs. Historical data shows pharma-specific business factors matter more than interest rates for stock performance.

09/27/2026, 5:30 AM • The Motley Fool

D-Wave Quantum vs. QuantumScape: Which Moonshot Tech Stock Is a Better Buy in 2026?

The article compares two early-stage quantum technology companies: D-Wave Quantum, which has commercial customers and $24.6M in revenue but is burning cash rapidly with a -1,444% net margin, and QuantumScape, a pre-revenue solid-state battery developer with a stronger cash cushion and clearer path to commercialization. The author recommends QuantumScape as the better speculative bet due to its financial runway, despite both being high-risk moonshot investments years from profitability.

09/26/2026, 10:09 AM • The Motley Fool

Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

09/25/2026, 8:30 AM • GlobeNewswire

Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

09/24/2026, 1:00 PM • GlobeNewswire

AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors

Artificial intelligence is accelerating vaccine adjuvant discovery and optimization, with over $140M in disclosed funding signaling a structural market shift. Major investments include Pfizer and NVIDIA's $80M joint venture into CytoReason and Ginkgo Bioworks' $31M contract with SaponiQx. AI tools are addressing key bottlenecks in antigen-adjuvant optimization and immune response prediction, supported by government initiatives globally. However, regulatory fragmentation, infrastructure gaps, and a shortage of AI-immunology talent remain challenges.

09/24/2026, 10:56 AM • GlobeNewswire

NASP Announces 2026 Industry Award Winners at Record-Breaking inSPire2026 Conference

The National Association of Specialty Pharmacy (NASP) recognized industry leaders and organizations at its annual conference in National Harbor, Maryland. Award recipients included Optum Specialty Pharmacy (Specialty Pharmacy of the Year), Van Chau from UC Davis Health (Pharmacist of the Year), and Pfizer (Manufacturer of the Year), among others. The record-breaking conference attracted over 2,400 specialty pharmacy professionals.

09/23/2026, 11:00 AM • GlobeNewswire

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?

The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.

09/22/2026, 12:02 PM • The Motley Fool

Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

09/22/2026, 10:59 AM • GlobeNewswire